Month: November 2012 (page 5 of 9)

an occasional drink is okay during pregnancy?

According to five paper from Danish researchers, it just might be. The work appeared in BJOG: An International Journal of Obstetrics and Gynaecology back in June An exerpt from the news release:

he definition of a drink in these papers comes from the Danish National Board of Health, which states one standard drink is equal to 12 grams of pure alcohol.
However, the amount of alcohol in a standard drink varies significantly from country to country. In the UK the volume of alcohol in a drink is measured in units and one unit of alcohol is defined as 7.9 grams.

1,628 women took part in the studies. The average maternal age was 30.9 years, 50.1% were first-time mothers, 12.1% were single and 31.4% reported smoking during pregnancy.

The papers looked at the effects of alcohol on IQ, attention span, executive functions such as planning, organisation, and self-control in five year old children.

Overall, the papers found that low to moderate weekly drinking in early pregnancy had no significant effect on neurodevelopment of children aged five years, nor did binge drinking. Focusing on children’s IQ and executive functions, no differences in test performance were observed between children whose mothers reported 1-4 or 5-8 drinks/week per week in pregnancy compared to children of abstaining mothers. However one finding showed that high levels of alcohol, intake of 9 or more drinks per week, was associated with lower attention span amongst five year olds…

I’d recommend not taking the risk. No matter what the study says.

an electromagnetic cure for cancer

The podcast of This American life that aired this past weekend offered an interesting glimpse into the world of cancer research. A pair of researchers, one a professor at Thomas Jefferson University and the other a music teacher, were studying whether pulsing sound waves could selectively kill cancer cells. The collaboration started off great but things started to go down hill.
One of the things that was interesting to see was how beginning researchers often get excited by preliminary data and think they’ve hit the jackpot. They don’t realize how critical the controls are. Nor do they realize how much effort it takes to reproduce and validate the experimental results. I have to admit the tedious work involved in validating results is part of what drove me out of the lab.

misfolded synuclein leads to parkinson’s spread

Image of a stained Lewy body

Research from my alma mater, The University of Pennsylvania, reveals some details on how Parkinson’s disease spreads throughout neural cells. The research led by Virginia Lee in the Department of Pathology and Laboratory Medicine has found that the protein α-synuclein plays a key role. When it is misfolded it passes through neural cells and causes cellular death and the formation of Lewy bodies. From Scientific American:

Parkinson’s disease has two distinct features: clumps of protein called Lewy bodies and a dramatic loss of nerve cells that produce the chemical messenger dopamine. When Lee’s team injected the misfolded α-synuclein into a part of the mouse brain rich in dopamine-producing cells, Lewy bodies began to form. This was followed by the death of dopamine neurons. Nerve cells that linked to those near the injection site also developed Lewy bodies, a sign that cell-to-cell transmission was taking place, say the researchers.

Greenamyre says that that is possible, but hasn’t yet been proved. “All of the cells affected in this paper were those directly in contact with the injection site,” he says.

Nevertheless, within six months of the injection, coordination of movement, grip strength and balance had all deteriorated in the mice, echoing what happens in people with Parkinson’s disease.

“It’s really pretty extraordinary,” says Eliezer Masliah, a neuroscientist at the University of California, San Diego. “We have been trying that experiment for a long time in the lab and we have not seen such dramatic effects.” The study lends theoretical support to the handful of biotechnology companies that are sponsoring clinical trials of α-synuclein antibodies for Parksinson’s, Masliah says. It should also spur research on how the protein gets in and out of cells, he adds.

Check out the details of the research in Science.

//sisaurgeegh.net/4/4535925